UM Ventures News
Monday, July 24, 2017
Living Pharma Inc., a cancer treatment startup out of the University of Maryland School of Medicine, has been acquired by Lentigen Technology.
Lentigen Technology Inc., a Miltenyi Biotec Company, Acquires University of Maryland, Baltimore CAR-T Cell Start-Up, Living Pharma, Inc.
Thursday, July 20, 2017
Lentigen Technology Inc., a subsidiary of Miltenyi Biotec GmbH, announced today its acquisition of immunotherapy start-up Living Pharma, Inc.
New Accelerator Seeks to Attract Connected Health and Fitness Startups from Across the Country to Baltimore
Wednesday, July 12, 2017
The 16-week M-1 Ventures program to provide dedicated startup support that facilitates the development of innovative health care solutions.
UMD, UMB Strategic Partnership Announces Expansion of Interdisciplinary Research at Cole Field House
Thursday, July 6, 2017
The University of Maryland, College Park and the University of Maryland, Baltimore are expanding the research and clinical scope at Cole Field House.
Monday, June 26, 2017
The NAI and IPO have ranked the University of Maryland No. 27 in the world and No. 11 among U.S. public institutions for patents awarded in 2016.
Cellth Systems and University of Maryland Enter License Agreement to Advance New Circulating-Tumor-Cell-Analysis Technology
Tuesday, June 13, 2017
Cellth Systems has been granted exclusive rights for the commercial development of cell-tethering that allows analysis of circulating tumor cells (CTCs).
Monday, June 12, 2017
The Institute for Bioscience and Biotechnology Research (IBBR) has been awarded a $6.0 million grant to develop a vaccine to prevent hepatitis C virus.
Friday, June 9, 2017
Serenta Biotechnology, which is based in Gaithersburg, is working to build on technology that was effective in animal trials.
Friday, June 2, 2017
A local startup wants to help doctors determine which drugs and chemotherapies will best treat different types of cancer.
Thursday, June 1, 2017
The University of Maryland, Baltimore (UMB) has granted worldwide, exclusive licensing rights for a new vaccine technology to Serenta Biotechnology, LLC.